John Marshall/LinkedIn
Dec 15, 2024, 15:22
John Marshall on zolbetuximab-clzb, a novel treatment for advanced gastric and GEJ cancers – NCODA
NCODA posted on LinkedIn:
“John Marshall, MD, Chief Medical Officer at the Lombardi Comprehensive Cancer Center (Georgetown University Medical Center), discusses zolbetuximab-clzb, a novel treatment for advanced gastric and gastroesophageal junction cancers. This therapy targets CLDN18.2, a protein overexpressed in these cancers, offering a new option for patients.”
Video attached to the post.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 15, 2024, 14:56
Dec 15, 2024, 14:56
Dec 15, 2024, 14:54
Dec 15, 2024, 14:52
Dec 15, 2024, 14:48
Dec 15, 2024, 14:31
Dec 15, 2024, 14:21
Dec 15, 2024, 14:21